India’s Life Sciences Sector at a Turning Point: Can Innovation Scale?

Introduction

India’s life sciences sector has reached a critical juncture. Over the past decade, the country has made tangible progress in biotech innovation, with patent filings increasing more than fourfold and innovation pipeline assets growing by 1.5 times. Yet the question remains whether India can translate these early wins into a sustainable innovation engine at scale. A new joint report from Boston Consulting Group (BCG) and HealthKois, an India-focused healthcare innovation fund, suggests that while the potential is real, structural gaps could hold the sector back.

Industry Context

India’s pharmaceutical industry has long been known for generic manufacturing and reverse engineering. However, the landscape is shifting. The report notes that biotech startups in India have grown by a factor of 1.6 over the past decade, and private capital directed toward healthcare innovation has increased sharply. Despite this, the innovation story remains “early and uneven,” with most momentum concentrated in late-stage translation. Early-stage research, clinical execution, regulatory consistency, and early-stage capital access remain weak.

Key Developments

Several milestones underscore the progress. Eleven novel drug assets have originated from India in the last decade, including first-in-class new chemical entities, indigenous CAR-T therapies, and AI-discovered molecules. For instance, Wockhardt’s intravenous antibiotic Zaynich (cefepime and zidebactam) received FDA approval in June 2026 for complicated urinary tract infections. Meanwhile, Pandorum Technologies raised $18 million in Series B funding in February 2026 to advance exosome-based therapies and scale global manufacturing.

Private equity and venture capital investment in Indian healthcare innovation grew 2.1 times over the past five years, reaching $731 million in fiscal year 2026. This influx of capital signals growing investor confidence, but the report warns that most of it is concentrated in later stages, leaving early-stage startups underfunded.

Market Implications

For global pharma and biotech companies, India’s innovation uptick presents both opportunities and challenges. On the one hand, India-origin science is increasingly being licensed by multinational pharmaceutical giants, and indigenously developed CAR-T therapies are being delivered at a fraction of global costs. This could eventually make India a competitive hub for novel drug discovery. On the other hand, structural inefficiencies—such as clinical trial approval times averaging 90 days versus 30 days in the U.S.—make it difficult to bring products to market quickly. Foreign partners may hesitate to collaborate if regulatory timelines remain unpredictable.

Challenges And Risks

The report identifies several key barriers to scaling innovation in India:

• Public funding gaps: Maximum grant sizes are around $52,000, compared to $2–3 million in the U.S. and EU.
• Low risk appetite: Indian venture capital firms are generally averse to high-risk biotech investments.
• Slow clinical approvals: Average clinical trial approval time of 90 days vs. ~30 days in the U.S.
• Import dependence: High-quality local suppliers for research-grade raw materials and reagents are scarce, especially for advanced modalities like gene therapy, leading to 30- to 45-day lead times.

These gaps limit the ability of Indian innovators to move quickly from lab to clinic and from clinic to market.

Future Outlook

The report outlines five key areas that could shape the next decade of India’s life sciences innovation:

1. Building India’s first generation of specialist biotech capital – dedicated funds with deep scientific expertise to support early-stage ventures. 2. Encouraging academia-industry partnerships – stronger collaboration to translate research into commercial products. 3. Creating fast-track regulatory pathways – streamlined approvals for novel therapies. 4. Building a domestic supply chain – reducing import reliance for raw materials and reagents. 5. Bridging the R&D talent quality gap – investing in specialized training and education.

Addressing these structural issues could unlock significant value. The report’s co-author and HealthKois co-founder Charles Janssen noted that capital willing to back science through early, uncertain years will be the difference between isolated successes and a durable innovation engine.

Conclusion

India’s life sciences sector is at a turning point, with a decade of progress laying the groundwork for a more innovative future. The path forward will depend heavily on how government, academia, and private capital collaborate to close the structural gaps identified in the BCG-HealthKois report. As global interest in India’s biotech potential grows, the country has a unique opportunity to evolve from a player in generics to a true hub for healthcare innovation. The next few years will test whether the ecosystem can make the leap from promising beginnings to scalable impact.